Shiga toxins (Stx1 and Stx2) are responsible for initiating haemolytic uraemic syndrome, a serious extraintestinal complication caused by enterohaemorrhagic Escherichia coli O157 : H7 infection in humans. Shiga toxins are classical AB5-type exotoxins, consisting of a globotriaosylceramide (Gb3)-binding B subunit pentamer and an enzymic A subunit. It is demonstrated in this study that Stx2 binds to human neutrophils by a non-classical mechanism that is independent of Gb3. In contrast, the investigation revealed that Stx2 binds to murine neutrophils by the classical Gb3-dependent mechanism. Moreover, whereas the human serum amyloid P (HuSAP) component inhibited Stx2 binding to murine neutrophils, HuSAP increased Stx2 binding to human neutrophils by 84.2 % (P≤0.002, Student's t-test). These observations may explain why HuSAP protects mice from the lethal effects of Stx2, whereas there is no indication that HuSAP plays a similar protective role in humans infected by E. coli O157 : H7.
ArmstrongG. D.,
MulveyG. L.,
MarcatoP.,
GrienerT. P.,
KahanM. C.,
TennentG. A.,
SabinC. A.,
ChartH.,
PepysM. B.2006; Human serum amyloid P component protects against Escherichia coli O157 : H7 Shiga toxin 2 in vivo : therapeutic implications for hemolytic-uremic syndrome. J Infect Dis 193:1120–1124[CrossRef]
BeutinL.,
KrauseG.,
ZimmermannS.,
KaulfussS.,
GleierK.2004; Characterization of Shiga toxin-producing Escherichia coli strains isolated from human patients in Germany over a 3-year period. J Clin Microbiol 42:1099–1108[CrossRef]
BitzanM.,
RichardsonS.,
HuangC.,
BoydB.,
PetricM.,
KarmaliM. A.1994; Evidence that Verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro
. Infect Immun 62:3337–3347
BrigottiM.,
CaprioliA.,
TozziA. E.,
TazzariP. L.,
RicciF.,
ConteR.,
CarnicelliD.,
ProcaccinoM. A.,
MinelliF.other authors2006; Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome. J Clin Microbiol 44:313–317[CrossRef]
DowneyG. P.,
DohertyD. E.,
SchwabB.III,
ElsonE. L.,
HensonP. M.,
WorthenG. S.1990; Retention of leukocytes in capillaries: role of cell size and deformability. J Appl Physiol 69:1767–1778
FlaglerM. J.,
StrasserJ. E.,
ChalkC. L.,
WeissA. A.2007; Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis. Infect Immun 75:760–765[CrossRef]
FraserM. E.,
FujinagaM.,
CherneyM. M.,
Melton-CelsaA. R.,
TwiddyE. M.,
O'BrienA. D.,
JamesM. N.2004; Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157 : H7. J Biol Chem 279:27511–27517[CrossRef]
FukudaM. N.,
DellA.,
OatesJ. E.,
WuP.,
KlockJ. C.,
FukudaM.1985; Structures of glycosphingolipids isolated from human granulocytes. The presence of a series of linear poly- N -acetyllactosaminylceramide and its significance in glycolipids of whole blood cells. J Biol Chem 260:1067–1082
GeelenJ. M.,
van der VeldenT. J.,
Te LooD. M.,
BoermanO. C.,
van den HeuvelL. P.,
MonnensL. A.2007; Lack of specific binding of Shiga-like toxin (Verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Nephrol Dial Transplant 22:749–755[CrossRef]
HawkinsP. N.,
TennentG. A.,
WooP.,
PepysM. B.1991; Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin Exp Immunol 84:308–316
HeadS. C.,
KarmaliM. A.,
LingwoodC. A.1991; Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J Biol Chem 266:3617–3621
KimuraT.,
TaniS.,
Matsumoto YiY.,
TakedaT.2001; Serum amyloid P component is the Shiga toxin 2-neutralizing factor in human blood. J Biol Chem 276:41576–41579[CrossRef]
KitovP. I.,
SadowskaJ. M.,
MulveyG.,
ArmstrongG. D.,
LingH.,
PannuN. S.,
ReadR. J.,
BundleD. R.2000; Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403:669–672[CrossRef]
KuligowskiM. P.,
KitchingA. R.,
HickeyM. J.2006; Leukocyte recruitment to the inflamed glomerulus: a critical role for platelet-derived P-selectin in the absence of rolling. J Immunol 176:6991–6999[CrossRef]
MarcatoP.,
Vander HelmK.,
MulveyG. L.,
ArmstrongG. D.2003; Serum amyloid P component binding to Shiga toxin 2 requires both A subunit and B pentamer. Infect Immun 71:6075–6078[CrossRef]
MengeC.,
EisenbergT.,
StammI.,
BaljerG.2006; Comparison of binding and effects of Escherichia coli Shiga toxin 1 on bovine and ovine granulocytes. Vet Immunol Immunopathol 113:392–403[CrossRef]
MulveyG.,
VanmaeleR.,
MrazekM.,
CahillM.,
ArmstrongG.1998; Affinity purification of Shiga-like toxin I and Shiga-like toxin II. J Microbiol Methods 32:247–252[CrossRef]
MulveyG. L.,
MarcatoP.,
KitovP. I.,
SadowskaJ.,
BundleD. R.,
ArmstrongG. D.2003; Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J Infect Dis 187:640–649[CrossRef]
TazzariP. L.,
RicciF.,
CarnicelliD.,
CaprioliA.,
TozziA. E.,
RizzoniG.,
ConteR.,
BrigottiM.2004; Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome. Cytometry B Clin Cytom 61:40–44
te LooD. M.,
MonnensL. A.,
van Der VeldenT. J.,
VermeerM. A.,
PreyersF.,
DemackerP. N.,
van Den HeuvelL. P.,
van HinsberghV. W.2000; Binding and transfer of Verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 95:3396–3402
te LooD. M.,
HeuvelinkA. E.,
de BoerE.,
NautaJ.,
van der WalleJ.,
SchroderC.,
van HinsberghV. W.,
ChartH.,
van de KarN. C.,
van den HeuvelL. P.2001a; Vero cytotoxin binding to polymorphonuclear leukocytes among households with children with hemolytic uremic syndrome. J Infect Dis 184:446–450[CrossRef]
te LooD. M.,
van HinsberghV. W.,
van den HeuvelL. P.,
MonnensL. A.2001b; Detection of Verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J Am Soc Nephrol 12:800–806